Sugi Predict

Sugi Predict / Compounds / SCHEMBL1679576

SCHEMBL1679576

SCHEMBL1679576

C[C@@H](Nc1cncc(Cl)n1)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 13/20 0.62
▸ CDK2 P24941 1/20 0.54
▸ RET P07949 1/20 0.53
▸ PDGFRB P09619 1/20 0.53
▸ KIT P10721 1/20 0.53
▸ SRC P12931 1/20 0.53
▸ PDGFRA P16234 1/20 0.53
▸ FLT1 P17948 1/20 0.53
▸ FLT4 P35916 1/20 0.53
▸ KDR P35968 1/20 0.53
▸ FRK P42685 1/20 0.53
▸ DDR1 Q08345 1/20 0.53
▸ LDHA P00338 1/20 0.52
▸ LDHB P07195 1/20 0.52
▸ DRD2 P14416 1/20 0.48
▸ HTR2A P28223 1/20 0.48
▸ HRH1 P35367 1/20 0.48
▸ CCNT1 O60563 1/20 0.47
▸ CDK9 P50750 1/20 0.47
▸ NUDT1 P36639 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1678955 1.00 CSF1R (0.62) CSF1RCDK2RETPDGFRBKIT
SCHEMBL1991252 1.00 CSF1R (0.62) CSF1RCDK2RETPDGFRBKIT
SCHEMBL1679263 0.86 CSF1R (0.59) CSF1RCDK2RETPDGFRBKIT
SCHEMBL13313087 0.84 AURKA (0.52) CSF1RRETPDGFRBKITSRC
SCHEMBL3557473 0.84 AURKA (0.52) CSF1RRETPDGFRBKITSRC
SCHEMBL6528042 0.84 CSF1R (0.53) CSF1RCDK2RETPDGFRBKIT
SCHEMBL3515072 0.84 AURKA (0.52) CSF1RRETPDGFRBKITSRC
SCHEMBL3149272 0.84 CSF1R (0.53) CSF1RCDK2RETPDGFRBKIT
SCHEMBL14705857 0.84 CSF1R (0.48) CSF1RCDK2RETPDGFRBKIT
SCHEMBL13478835 0.84 CSF1R (0.48) CSF1RCDK2RETPDGFRBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689739-B1 AZOLE-BASED KINASE INHIBITORS YM BIOSCIENCES AUSTRALIA PTY (AU) 2016-03-30 — — EP disclosed
EP-1689739-B1 AZOLE-BASED KINASE INHIBITORS YM BIOSCIENCES AUSTRALIA PTY (AU) 2016-03-30 — — EP disclosed
US-8329737-B2 Benzimidazoles as selective kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2012-12-11 — — US disclosed
US-8329737-B2 Benzimidazoles as selective kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2012-12-11 — — US disclosed
EP-1704145-B1 SELECTIVE KINASE INHIBITORS YM BIOSCIENCES AUSTRALIA PTY (AU) 2012-06-13 — — EP disclosed
US-20110082142-A1 SELECTIVE KINASE INHIBITORS CYTOPIA RESEARCH PTY LTD (AU) 2011-04-07 — — US disclosed
US-20110082142-A1 SELECTIVE KINASE INHIBITORS CYTOPIA RESEARCH PTY LTD (AU) 2011-04-07 — — US disclosed
US-7737143-B2 Substituted pyrazines as kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-06-15 — — US disclosed
US-7737143-B2 Substituted pyrazines as kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-06-15 — — US disclosed
US-7737143-B2 Substituted pyrazines as kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-06-15 — — US disclosed
US-20060270687-A1 Kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2006-11-30 — — US disclosed
US-20060241112-A1 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2006-10-26 — — US disclosed
US-7122550-B2 Protein kinase inhibitors CYTOPIA PTY LTD (AU) 2006-10-17 — — US disclosed
US-20060148824-A1 Protein kinase inhibitors CYTOPIA RESEARCH PTY LTD (AU) 2006-07-06 — — US disclosed
US-20060069084-A1 Methods of inhibiting kinases CYTOPIA RESEARCH PTY LTD (AU) 2006-03-30 — — US disclosed
US-20050004140-A1 Kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2005-01-06 — — US disclosed
US-20040235862-A1 For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2004-11-25 — — US disclosed
US-20040102455-A1 Method of inhibiting kinases CYTOPIA RESEARCH PTY LTD (AU) 2004-05-27 — — US disclosed
EP-1363702-A1 METHODS OF INHIBITING KINASES Cytopia PTY Ltd (AU) 2003-11-26 — — EP disclosed
WO-2002060492-A1 METHODS OF INHIBITING KINASES CYTOPIA PTY LTD (AU) 2002-08-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235862-A1 For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer LCK, IRAK1, MAP2K5 CSF1R 1399/4885CDK2 592/4885RET 963/4885
US-20040102455-A1 Method of inhibiting kinases JAK2, JAK1, JAK3 CSF1R 1201/4885CDK2 58/4885RET 492/4885
US-20060270687-A1 Kinase inhibitors MAP3K20, MAP3K1, MAP3K19 CSF1R 1724/4885CDK2 119/4885RET 266/4885
US-20060241112-A1 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states MAP4K2, MAP4K5, MAP4K4 CSF1R 3043/4885CDK2 313/4885RET 548/4885
US-20110082142-A1 SELECTIVE KINASE INHIBITORS LCK, CHUK, CSK CSF1R 671/4885CDK2 69/4885RET 219/4885
US-20050004140-A1 Kinase inhibitors MAP3K20, MAP3K1, MAP3K19 CSF1R 1724/4885CDK2 119/4885RET 266/4885
US-20060069084-A1 Methods of inhibiting kinases JAK2, JAK1, JAK3 CSF1R 1221/4885CDK2 55/4885RET 478/4885
US-20060148824-A1 Protein kinase inhibitors MAP3K20, MAP4K2, MAP3K1 CSF1R 3034/4885CDK2 79/4885RET 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.